This is good news potentially. TL1A have the potential of helping with inflammatory bowel disease, and arthritis and inflammatory diseases but it won’t come out, until half a decade from now.
Biotech stock investors are hoping for a repeat performance from the suite of TL1A drugs.
Proving The Drug’s Merit
First, the companies are looking to prove the drugs’ merit in ulcerative colitis and Crohn’s disease. So far, that venture has paid off handsomely for the biotech stocks involved.
Comments are closed.